Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence
Werte in diesem Artikel
MADISON, Wis., Oct. 15, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced that, effective as of today, Suzanne Winter has returned from her temporary medical leave and assumed her full duties as President and Chief Executive Officer. Sandeep Chalke, who has served as interim CEO during Ms. Winter's absence, will continue in his position as Senior Vice President and Chief Commercial Officer.
"On behalf of the entire Board of Directors, I am delighted Suzanne has resumed her role as CEO. We appreciate the leadership provided by Sandeep in her absence and the support of the global Accuray team," said Joseph Whitters, Chairman of the Board at Accuray.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.
Investor Contact
Aman Patel, CFA
Investor Relations, ICR-Westwicke
+1 (443) 450-4191
aman.patel@westwicke.com
Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-president-and-chief-executive-officer-suzanne-winter-returns-from-medical-leave-of-absence-302276241.html
SOURCE Accuray Incorporated
Ausgewählte Hebelprodukte auf Accuray
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Accuray
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Accuray IncShs
Analysen zu Accuray IncShs
Datum | Rating | Analyst | |
---|---|---|---|
30.11.2017 | Accuray Buy | Lake Street | |
22.12.2015 | Accuray Sector Perform | RBC Capital Markets | |
01.05.2015 | Accuray Buy | Dougherty & Company LLC | |
12.01.2015 | Accuray Outperform | Northland Capital | |
06.11.2007 | Accuray günstig bewertet | Global Biotech Investing |
Datum | Rating | Analyst | |
---|---|---|---|
30.11.2017 | Accuray Buy | Lake Street | |
01.05.2015 | Accuray Buy | Dougherty & Company LLC | |
12.01.2015 | Accuray Outperform | Northland Capital | |
06.11.2007 | Accuray günstig bewertet | Global Biotech Investing |
Datum | Rating | Analyst | |
---|---|---|---|
22.12.2015 | Accuray Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Accuray IncShs nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen